Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Poster display session

15P - KRAS mutation in metastatic non-small cell lung carcinoma (NSCLC) - the Indian subcontinent experience from a tertiary cancer center!

Date

15 Oct 2022

Session

Poster display session

Presenters

Anindya Mukherjee

Citation

Annals of Oncology (2022) 33 (suppl_8): S1383-S1430. 10.1016/annonc/annonc1095

Authors

A. Mukherjee1, S. Nathany2, M. Sharma2, A. B Patel1, U. Batra1

Author affiliations

  • 1 Rajiv Gandhi Cancer Institute and Research Centre, New Delhi/IN
  • 2 Rajiv Gandhi Cancer Institute and Research Centre, 110085 - New Delhi/IN
More

Abstract 15P

Background

The pathbreaking discovery of sotorasib as KRAS G12C inhibitor has revolutionized the prognostic outcome of KRAS mutated metastatic NSCLC. This is a single centre experience of KRAS mutated NSCLC in an Indian cohort, underscoring the unmet urgent need of sotorasib in this part of the world.

Methods

Among the 3899 NSCLC patients registered between 2016 to 2020, 163 patients were tested for KRAS alterations, of which 50 patients were confirmed to harbor a KRAS variant by molecular testing. Appropriate statistical analysis was done to compare G12C and non-G12C subtypes, including their survival outcomes.

Results

Median age was 63 years (range: 36-81years) with a preponderance of non-G12C mutations in both sexes. Smokers were higher in G12C group (16 vs 4 pts, p=0.09). G12C group showed lesser PDL1 expression (>1%) than non-G12C group (13 vs. 15 pts, p=0.09). Molecular analysis revealed 3 main types of KRAS mutations: G12C, G12V and G12D in 17 (34%), 9(18%) and 6 (12%) pts respectively. None of them had KRAS complex mutations. The co-mutations predominantly detected included TP53 in 7 (14%), STK11 in 3 (6%), FGFR4 in 4 (8%), PIK3CA, EGFR and ALK in 2 cases each, BRAF and CTNNB1 in 1 case each. Co-mutations were significantly more frequent in the non-G12C group (p<0.05). 36 patients received chemotherapy and rest were lost to follow up. The median PFS and OS of the entire cohort on chemotherapy were 5.4 months (mo) and 11.1 mo respectively. The median PFS and OS of G12C vs non-G12C groups were 6.4 mo (95% CI: 2.8-11.8) vs 3.8 mo (95%CI: 2.9-7.7) and 15.2 mo (95% CI: 9.8-17.2) vs 16.1 mo (95% CI: 10.7-19.3) respectively. With a median follow-up of 14.3 mo, both PFS and OS were not statistically significant between the groups, p=0.08 and 0.20 respectively.

Conclusions

This is by far the largest experience from India of KRAS mutated NSCLC, comparing G12C with other KRAS mutants. Despite limitations of retrospective nature, small sample size, heterogeneity in the cohort and missing data points, and limited molecular profiling this study is relevant in the light of approval of targeted therapy, sotorasib, which is currently unavailable in this country.

Legal entity responsible for the study

The authors.

Funding

Has not received any funding.

Disclosure

All authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.